The Health Care Portfolio, Series 25 ("Trust") seeks to maximize total return through capital appreciation with a secondary objective of current income.
|Wrap Fee Price||$9.9852|
|Remaining Deferred Sales Charge||$0.2250|
|Mandatory Maturity Date||7/13/2020|
|NASDAQ Ticker Symbol||CHCRZX|
|Inception Unit Price||$10.0000|
|Inception Liquidation Price||$9.7750|
|Deferred Sales Charge Dates||
|Number of Holdings||40|
|Historical Annual Dividend Distribution||$0.0951|
All data is subject to change daily. Data may differ from the prospectus due to different data sources or market changes. Please refer to prospectus for additional information about the trust including the portfolio section criteria. Source: FactSet Research Systems Inc. unless otherwise noted. The total percentages may not be equal to 100% due to rounding. N/A indicates that certain securities have not been identified and/or classified by the data provider. A unit is a combination of securities or types of securities traded together.
|Weighted Average Price/Earnings (P/E) Ratio||76.10|
|Weighted Average Price/Book (P/B) Ratio||7.92|
|Weighted Average Market Cap (MM)||$97,028.09|
|US Common Stock||100.00%|
|Health Care Equipment & Supplies||25.59%|
|Health Care Providers & Services||19.45%|
|Life Sciences Tools & Services||6.26%|
Past performance is no guarantee of future results. Investment returns and principal value will fluctuate with changes in market conditions. Investors' units, when redeemed, may be worth more or less than their original cost.
Principal Investment Strategy
Under normal circumstances, the Trust invests at least 80% of the value of its assets in stocks of companies that are classified as being in the health care sector by the Global Industry Classification Standard (“GICS”), or are believed by the Sponsor to have a significant level of revenues directly derived from health care related products and services. The Sponsor selects securities for the portfolio that it believes have the potential to achieve the Trust’s investment objective.
The Sponsor selects U.S.-traded securities that it believes are core holdings of a health care portfolio. To select the portfolio, the Sponsor follows a disciplined process that includes both quantitative and qualitative analysis. The Sponsor begins with the securities of companies that are classified as being in the health care sector by GICS, or are believed by the Sponsor to have a significant level of revenues directly derived from health care related products and services, and are either components of the Russell 3000 Index (“R3K”) or have market capitalizations larger than the smallest company within the R3K. The Sponsor then reduces the size of this universe by performing quantitative screening, which may be primarily based on, but not limited to, the following factors:
• Valuation. The Sponsor may screen for reasonably valued securities based on measures such as price-to-earnings, price-to-book, and price-to-cash flow.
• Growth. The Sponsor may screen for companies with a history of better than average growth of revenues and earnings.
• Profitability. The Sponsor may screen for companies with a history of consistent and high profitability as measured by return-on-assets, return-on-equity, gross margin and net margin.
The Sponsor then reduces the securities by performing qualitative analysis, which may be primarily based on, but not limited to, the following factors:
• Balance Sheet. The Sponsor favors companies which possess overall financial strength and exhibit balance sheet improvements relative to their peers and the marketplace.
• Industry Leadership. The Sponsor favors companies which possess a strong competitive position among their domestic and global peers.
• Valuation. The Sponsor favors stocks for which valuations appear to be attractive based on measures such as price-to-earnings, price-to-book, and price-to-cash flow.
• Growth. The Sponsor favors companies with a history of (and prospects for) better than average growth of revenues and earnings.
• Profitability. The Sponsor favors companies with a history of (and prospects for) consistent and high profitability as measured by return-on-assets, return-on-equity, gross margin and net margin.
Risks and Other Considerations
As with all investments, you may lose some or all of your investment in the Trust. No assurance can be given that the Trust’s investment objective will be achieved. The Trust also might not perform as well as you expect. This can happen for reasons such as these:
• Securities prices can be volatile. The value of your investment may fall over time. Market value fluctuates in response to various factors. These can include stock market movements, purchases or sales of securities by the Trust, government policies, litigation, and changes in interest rates, inflation, the financial condition of the securities’ issuer or even perceptions of the issuer. Units of the Trust are not deposits of any bank and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
• The Trust is concentrated in the health care sector. As a result, the factors that impact the health care sector will likely have a greater effect on this Trust than on a more broadly diversified Trust. General risks of companies in the health care sector include extensive competition, generic drug sales, the loss of patent protection, product liability litigation and increased government regulation.
• The Trust invests significantly in the securities of biotechnology companies. As a result, the factors that impact the biotechnology industry will likely have a greater effect on this Trust than on a more broadly diversified Trust. Biotechnology companies face intense competition and the potential for rapid product obsolescence. A biotechnology company’s valuation can be based largely on the potential or actual performance of a limited number of products and can accordingly be greatly affected if one of its products proves unsafe, ineffective or unprofitable. Biotechnology companies are subject to regulation by, and the restrictions of, the Food and Drug Administration, the Environmental Protection Agency, state and local governments, and foreign regulatory authorities. Biotechnology companies may be adversely affected by the loss or impairment of intellectual property rights or changes in government regulations.
• The Trust is concentrated in the securities of health care equipment and supplier companies. As a result, the factors that impact the health care equipment and supplier industry will likely have a greater effect on this Trust than on a more broadly diversified Trust. Health care equipment and supplier companies may be affected by rising costs of medical products, devices and services; an increased emphasis on outpatient services; pricing pressure; extensive government regulations; restrictions on government reimbursement for medical expenses; industry innovation; changes in technologies and litigation.
• The Trust invests significantly in the securities of pharmaceutical companies. As a result, the factors that impact the pharmaceuticals industry will likely have a greater effect on this Trust than on a more broadly diversified Trust. Companies in the pharmaceuticals industry can be significantly affected by government approval of products and services, government regulation, reimbursement rates and patent expirations and protection. Additionally, pharmaceutical companies can be adversely affected by intense competition, dependency on a limited number of products, obsolescence of products and product liability claims.
• The Trust includes securities issued by small-capitalization and mid-capitalization companies. These securities customarily involve more investment risk than large-capitalization companies. Small-capitalization and mid-capitalization companies may have limited product lines, markets or financial resources and may be more vulnerable to adverse general market or economic developments.
• Share prices or dividend rates on the securities in the Trust may decline during the life of the Trust. There is no guarantee that share prices of the securities in the Trust will not decline and that the issuers of the securities will declare dividends in the future and, if declared, whether they will remain at current levels or increase over time.
• Inflation may lead to a decrease in the value of assets or income from investments.
• The Sponsor does not actively manage the portfolio. The Trust will generally hold, and may, when creating additional units, continue to buy, the same securities even though a security’s outlook, market value or yield may have changed.
See “Investment Risks” in Part A of the prospectus and “Risk Factors” in Part B of the prospectus for additional information.
Please see the Trust prospectus for more complete risk information.
Unit Investment Trusts are fixed, not actively managed and should be considered as part of a long-term strategy. Investors should consider their ability to invest in successive portfolios, if available, at the applicable sales charge. UITs are subject to annual fund operating expenses in addition to the sales charge. Investors should consult an attorney or tax advisor regarding tax consequences associated with an investment from one series to the next, if available, and with the purchase or sale of units. Guggenheim Funds Distributors, LLC does not offer tax advice.
Read a prospectus and summary prospectus (if available) carefully before investing. It contains the investment objective, risks charges, expenses and the other information, which should be considered carefully before investing. To obtain a prospectus and summary prospectus (if available) click here or call 800.820.0888.
Investing involves risk, including the possible loss of principal.
Guggenheim Investments represents the investment management business of Guggenheim Partners, LLC ("Guggenheim"), which includes Security Investors, LLC ("SI"), Guggenheim Funds Investments Advisors, LLC ("GFIA") and Guggenheim Partners Investment Management ("GPIM") the investment advisors to the referenced funds.
© 2018 Guggenheim Investments. All Rights Reserved.
Research our firm with FINRA Broker Check.
• Not FDIC Insured • No Bank Guarantee • May Lose Value
This website is directed to and intended for use by citizens or residents of the United States of America only. The material provided on this website is not intended as a recommendation or as investment advice of any kind, including in connection with rollovers, transfers, and distributions. Such material is not provided in a fiduciary capacity, may not be relied upon for or in connection with the making of investment decisions, and does not constitute a solicitation of an offer to buy or sell securities. All content has been provided for informational or educational purposes only and is not intended to be and should not be construed as legal or tax advice and/or a legal opinion. Always consult a financial, tax and/or legal professional regarding your specific situation. Investing involves risk, including the possible loss of principal.